Imai Y, Abe K, Otsuka Y, Sakurai Y, Ito T, Sato M, Haruyama T, Omata K, Hiwatari M, Yoshinaga K
Jpn Heart J. 1980 Nov;21(6):793-802. doi: 10.1536/ihj.21.793.
Captopril (SQ 14225), an orally active converting enzyme inhibitor, was administered in a dose of 50 mg to 12 normotensive subjects (Group I), 26 essential hypertensive patients (Group II), and 8 renovascular hypertensive patients (Group III). In Group III, 5 of the 8 patients had control plasma renal activity (PRA) similar to those in Groups I and II patients, but the PRA response to the administration of captopril was greater in 7 of the 8 patients than those in Groups I and II. These 7 patients had either bilateral or unilateral main renal artery stenosis. Captopril caused no increase in PRA in the remaining 1 who had unilateral renal artery stenosis with contralateral renin aplasia. It is concluded that this provocation test is useful as a screening procedure for the diagnosis of renovascular hypertension.
卡托普利（SQ 14225）是一种口服有效的转换酶抑制剂，以50毫克的剂量给予12名血压正常的受试者（第一组）、26名原发性高血压患者（第二组）和8名肾血管性高血压患者（第三组）。在第三组中，8名患者中有5名的血浆肾素活性（PRA）与第一组和第二组患者相似，但8名患者中有7名对卡托普利给药的PRA反应大于第一组和第二组。这7名患者患有双侧或单侧主肾动脉狭窄。卡托普利对其余1名患有单侧肾动脉狭窄伴对侧肾素发育不全的患者的PRA没有影响。结论是，这种激发试验作为肾血管性高血压诊断的筛查程序是有用的。
